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Abstract. 
 
Previous studies have indicated that neuro-
endocrine cells store monoamines and acetylcholine 
(ACh) in different secretory vesicles, suggesting that 
the transport proteins responsible for packaging these 
neurotransmitters sort to distinct vesicular compart-
ments. Molecular cloning has recently demonstrated 
that the vesicular transporters for monoamines and 
ACh show strong sequence similarity, and studies of 
the vesicular monoamine transporters (VMATs) indi-
cate preferential localization to large dense core vesi-
cles (LDCVs) rather than synaptic-like microvesicles 
(SLMVs) in rat pheochromocytoma PC12 cells. We 
now report the localization of the closely related vesic-
ular ACh transporter (VAChT). In PC12 cells, VAChT 
differs from the VMATs by immunofluorescence and 
fractionates almost exclusively to SLMVs and endo-
somes by equilibrium sedimentation. Immunoisolation 
further demonstrates colocalization with synaptophysin 
on SLMVs as well as other compartments. However, 
small amounts of VAChT also occur on LDCVs. Thus, 
VAChT differs in localization from the VMATs, which 
sort predominantly to LDCVs. In addition, we demon-
strate ACh transport activity in stable PC12 transfor-
mants overexpressing VAChT. Since previous work has 
suggested that VAChT expression confers little if any 
transport activity in non-neural cells, we also deter-
mined its localization in transfected CHO fibroblasts. 
In CHO cells, VAChT localizes to the same endosomal 
compartment as the VMATs by immunofluorescence, 
density gradient fractionation, and immunoisolation 
with an antibody to the transferrin receptor. We have 
also detected ACh transport activity in the transfected 
CHO cells, indicating that localization to SLMVs is not 
required for function. In summary, VAChT differs in 
localization from the VMATs in PC12 cells but not 
CHO cells.
 
R
 
egulated 
 
release by exocytosis involves specialized
secretory vesicles that undergo fusion with the
plasma membrane after the appropriate stimula-
tion (7, 51, 53). In neuroendocrine cells, the vesicles that
undergo regulated exocytosis belong to two distinct classes,
synaptic vesicles (SVs)
 
1
 
 and large dense core vesicles (LD-
CVs; 29, 37). SVs in neurons or synaptic-like microvesicles
(SLMVs) in endocrine cells are small, clear vesicles that
contain classical neurotransmitters such as acetylcholine
(ACh), 
 
g
 
-aminobutyric acid (GABA), and glutamate. They
cluster over the presynaptic nerve terminal and mediate
the extremely rapid, precise release required for informa-
tion processing. In contrast, LDCVs (or in endocrine cells,
secretory granules) are larger vesicles with an elec-
trodense core that contain neural peptides (or in the case
of endocrine cells, hormones). LDCVs also differ in loca-
tion from SVs, occurring in the cell body and dendrites as
well as the nerve terminal. Further, different stimuli in-
duce the exocytosis of LDCVs and SVs, and the release of
LDCVs occurs over a longer time frame, consistent with the
action of peptides as neuromodulators (37). The mecha-
nism by which signaling molecules enter these secretory
vesicles also differs between SVs and LDCVs. Most pro-
teins enter the secretory compartment by co-translational
translocation into the lumen of the endoplasmic reticulum
(59). Thus, neural peptides already occur within the secre-
tory compartment before they undergo sorting into LD-
CVs (the regulated secretory pathway). In contrast, classi-
cal transmitters are synthesized in the cytoplasm or appear
there after reuptake from the extracellular space, requir-
ing specific transport from the cytoplasm into secretory
vesicles.
Previous work has identified four distinct vesicular
transport activities for classical neurotransmitters (17, 50).
These include one transport activity for monoamines, an-
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Abbreviations used in this paper
 
: ACh, acetylcholine; ChAT, choline
acetyltransferase; LDCVs, large dense core vesicles; SLMVs, synaptic-like
microvesicles; SV, synaptic vesicle; TfR, transferrin receptor; VAChT, ve-
sicular ACh transporter; VMAT, vesicular monoamine transporters.
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other for ACh, a third for GABA and glycine, and a
fourth for glutamate. In contrast to the plasma membrane
transporters that terminate transmitter action by removing
them from the synaptic cleft and use the Na
 
1
 
 gradient
across the plasma membrane, the vesicular transporters
use the H
 
1
 
 electrochemical gradient across the vesicle mem-
brane generated by a vacuolar H
 
1
 
-ATPase. In particular,
vesicular amine transport involves the exchange of two lu-
menal protons for one cytoplasmic monoamine (26), and
ACh transport also uses primarily the chemical compo-
nent of the electrochemical gradient (2) whereas vesicular
GABA and glutamate transport depend more heavily on
the electrical component (24, 30, 38).
Previous studies have indicated that neuroendocrine
cells store monoamines and ACh in distinct vesicular com-
partments, suggesting that the transporters responsible for
packaging these transmitters localize to distinct secretory
vesicles. Monoamines are stored in the chromaffin gran-
ules (LDCVs) of adrenal medullary cells and SVs of cen-
tral neuronal populations (55). ACh, on the other hand,
has been reported to occur only in SVs (45). Interestingly,
rat pheochromocytoma PC12 cells store both monoamines
and ACh (22, 23, 39). Density gradient fractionation of
PC12 cells has suggested that whereas monoamines occur
in LDCVs, ACh occur almost exclusively in other vesicles
such as SLMVs (3, 5). Thus, PC12 cells provide a model
system to study the localization and sorting of both vesicu-
lar monoamine and ACh transporters within the same cell
line.
Molecular cloning has recently demonstrated that the
two vesicular monoamine transporters (VMATs) and a
vesicular ACh transporter (VAChT) show close sequence
similarity (16, 50). The VMATs were originally cloned by
selection in the parkinsonian neurotoxin 
 
N
 
-methyl–4-phe-
nylpyridinium (MPP
 
1
 
; 18, 34, 35). The VMATs protect
against MPP
 
1
 
 toxicity by sequestering the toxin in mito-
chondria and away from its primary site of action in mito-
chondria, implicating their activity in neural degeneration
as well as signaling. Adrenal medullary and other non-
neuronal cells express VMAT1, whereas central neuronal
populations, sympathetic neurons, and histamine-contain-
ing cells express the closely related VMAT2 (46, 60). The
sequences of the two proteins originally showed similarity
only to a class of bacterial antibiotic resistance proteins,
supporting a role in detoxification and defining a novel
vertebrate gene family. The 
 
Caenorhabditis elegans
 
 mutant
 
unc-17
 
 has a selective defect in cholinergic neurotransmis-
sion, and the sequence of the gene shows similarity to the
VMATs, suggesting that the 
 
unc-17
 
 gene encodes a vesicu-
lar ACh transporter (1). Vertebrate homologues have since
been identified and show strong similarity to both 
 
unc-17
 
and the VMATs (4, 19, 48). Although VAChT expression
occurs selectively in cholinergic neurons, apparently as a
result of expression from the same genomic locus that en-
codes the biosynthetic enzyme choline acetyltransferase
(ChAT; 4, 19), it has been difficult to demonstrate that the
cDNA confers vesicular transport activity by heterologous
expression in mammalian cell lines. Recently, however, sta-
ble PC12 transformants expressing VAChT have been shown
to transport ACh (58).
To examine the localization of the vesicular transport
proteins, we have raised antibodies to both rat VMATs
and VAChT. As anticipated, adrenal chromaffin cells ex-
press VMAT1 on LDCVs, and PC12 cells show preferential
expression of VMAT1 on LDCVs by both immunofluo-
rescence and density gradient fractionation (36). Nonethe-
less, PC12 cells contain low but clearly detectable amounts
of VMAT1 on SLMVs as well. In contrast, VAChT local-
izes to SVs by immunoelectron microscopy of brain sec-
tions (21). To determine whether VAChT also sorts to
SLMVs in the same cells where the closely related VMAT1
appears in LDCVs, we have now examined the localiza-
tion of VAChT in PC12 cells. By immunofluorescence, den-
sity gradient fractionation, and immunoisolation, VAChT
localizes to SLMVs and endosomes, but small amounts
also occur on LDCVs. Although VAChT and VMAT lo-
calization differ in PC12 cells, both transport proteins are
found on the same endosomal vesicles in CHO cells. In ad-
dition, ACh transport activity does not appear to depend
on localization to SLMVs, since membranes from trans-
fected CHO cells as well as PC12 cells exhibit specific up-
take of ACh.
 
Materials and Methods
 
Cell Culture
 
CHO cells were maintained in Ham’s F12 medium with 5% FCS and
PC12 cells in DME with 10% horse serum and 5% FCS. All cultures were
incubated at 37
 
8
 
C in 5% CO
 
2
 
 and contained penicillin and streptomycin.
Stable transformants were produced by cotransfection with the selectable
marker for resistance to neomycin as previously described (34, 35). Briefly,
10 
 
m
 
g of VAChT cDNA in the plasmid expression vector pcDNA-Amp
(Invitrogen Corp., Carlsbad, CA) was coprecipitated with 1 
 
m
 
g RSV-neo
and transfected into CHO and PC12 cells at 20% density using the stan-
dard calcium phosphate technique. 2 d after transfection, the cells were se-
lected in 400 
 
m
 
g/ml G418. Approximately 2 wk after transfection, surviv-
ing colonies were picked and immunostained for VAChT expression. For
immunofluorescence, PC12 cells were treated with nerve growth factor
(50 ng/ml) for at least 3 d before staining. To label dense core vesicles for
cell fractionation, PC12 cells were grown in standard medium containing
2.5 
 
m
 
Ci/ml [
 
3
 
H]norepinephrine (Dupont NEN, Boston, MA) for at least 6 h.
 
Antibody Production
 
The peptide CEDDYNYYSRS from the COOH terminus of rat VAChT
predicted by the cDNA was synthesized and coupled to keyhole limpet
hemocyanin (KLH) using 
 
m
 
-maleimidobenzoyl 
 
N
 
-hydroxysuccinimide es-
ter (MBS) as previously described (36, 46). 1 mo after intradermal inocu-
lation with 100 
 
m
 
g peptide conjugate in complete Freund’s adjuvant, the
rabbits were boosted with an additional subcutaneous 100-
 
m
 
g peptide con-
jugate in incomplete Freund’s adjuvant and sera collected 10 d later to
identify the animals producing antibody to VAChT. Subsequent boosts
were performed under similar conditions and serum collected 10–12 d
later. The serum was used for both immunofluorescence studies and West-
ern analysis without further adsorption or purification.
 
Immunofluorescence
 
For immunostaining, cells were plated onto glass coverslips coated with
poly-
 
d
 
-lysine and Matrigel (Collaborative Research, Inc., Waltham, MA) as
previously described (6) and fixed with 4% paraformaldehyde in 0.1 M
phosphate buffer, pH 7.2. After permeabilization and blocking in phos-
phate-buffered saline containing 2% bovine serum albumin, 1% fish skin
gelatin, and 0.02% saponin for 1 h, the cells were incubated with primary
antibody in the same buffer for 1.5 h at room temperature, washed three
times for 10 min each in the same buffer, incubated an additional 1 h at
room temperature with the appropriate secondary antibody diluted 1:100
in the same buffer, and washed again three times for 5 min each. To detect
VAChT primary antibody, the secondary antibody was a goat anti–rabbit
antibody conjugated to fluorescein (Cappel Laboratories, Malvern, PA).
For the monoclonal antibodies to synaptophysin (Sigma Chemical Co., St.
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Louis, MO) and chromogranin B (a generous gift of W. Huttner, Univer-
sity of Heidelberg, Heidelberg, Germany), we used goat anti–mouse anti-
bodies conjugated to rhodamine (Cappel Laboratories). To determine the
localization of transferrin receptors, CHO cells were pre-incubated in se-
rum-free medium for 60 min at 37
 
8
 
C to deplete endogenous transferrin
and then incubated with 50 
 
m
 
g/ml human transferrin conjugated to Texas
red (Molecular Probes, Inc., Eugene, OR) for 30 min, rinsed quickly in
cold medium, and fixed as above before immunostaining.
For confocal laser microscopy, immunofluorescence was performed as
described above using secondary anti–rabbit antibodies conjugated to Cy3
and anti–mouse antibodies conjugated to Cy5 (Jackson ImmunoResearch
Labs, West Grove, PA). The staining was then visualized with a confocal
laser microscope (Bio Rad, Hercules, CA) and the images processed using
the NIH Image program and Adobe Photoshop (Adobe Systems, Inc.,
Mountain View, CA).
 
Membrane Preparation and Cell Fractionation
 
Cell membranes were prepared as previously described (36). Briefly, the
cells were harvested by scraping, pelleted, and resuspended in PBS con-
taining 5 mM MgEGTA, 1 
 
m
 
g/ml leupeptin, and 0.2 mM diisopropylfluo-
rophosphate (DFP) for homogenization at 10 
 
m
 
m clearance. Debris was
then pelleted at 750 
 
g
 
 for 5 min and the resulting postnuclear supernatant
either loaded onto the appropriate gradient for fractionation or the mem-
branes pelleted at 35,000 rpm for 45 min in a Beckman SW50.1.
For cell fractionation by equilibrium sedimentation, the postnuclear su-
pernatant was layered onto a linear 0.6–1.6 M sucrose gradient containing
10 mM Hepes, pH 7.2, and centrifuged at 30,000 rpm for 6 h in an SW41
rotor (Beckman Instruments, Fullerton, CA) at 4
 
8
 
C. Fractions were col-
lected from the top of the tube and stored at 
 
2
 
70
 
8
 
C until analyzed.
For velocity sedimentation, the postnuclear supernatant was layered
over a 5–25% glycerol gradient containing Hepes-buffered saline (0.15 M
NaCl, 25 mM Hepes, pH 7.2) with 5 mM EGTA and centrifuged at 48,000
rpm for 1 h in an SW50.1 rotor (11). Fractions were collected as described
above.
LDCV purification involved sequential fractionation through two den-
sity gradients (52). After incubating the PC12 cells with 2.5 
 
m
 
Ci/ml [
 
3
 
H]nor-
epinephrine overnight to label the LDCVs, a postnuclear supernatant was
prepared as described above in 137 mM NaCl, 5 mM KCl, 0.6 mM Na
 
2
 
HPO
 
4
 
,
25 mM Tris-HCl, pH 7.4 (TBS) containing 5 mM MgEGTA, 1 
 
m
 
g/ml leu-
peptin and 0.2 mM DFP. The postnuclear supernatant was then layered
onto a 0.3–1.2 M sucrose gradient and sedimented at 25,400 rpm in an
SW40 rotor (Beckman Instruments) for 30 min at 4
 
8
 
C. The fractions were
collected and the radioactivity in an aliquot of each determined by scintil-
lation counting. Pooled fractions containing the bulk of the radioactivity
were then loaded onto a 0.6–1.6 M sucrose gradient and sedimented to
equilibrium at 30,000 rpm in an SW40 for 12 h at 4
 
8
 
C.
 
N-Glycanase Digestion
 
PC12 or CHO cells were harvested and lysed in PBS containing 0.5% NP-40
and protease inhibitors. The nuclei were then sedimented and 100 
 
m
 
g pro-
tein from the supernatant digested overnight at 37
 
8
 
C in PBS containing
1.5% NP-40 with or without 0.3 U 
 
N
 
-glycanase (Genzyme Corp., Boston,
MA). The reaction was then stopped by dilution in sample buffer and the
products analyzed by Western analysis.
 
Western Analysis
 
Aliquots of membrane preparations and the fractions from density gradi-
ents were diluted in 2
 
3
 
 sample buffer and separated by electrophoresis
through discontinuous 10% SDS–polyacrylamide gels before electrotrans-
fer to nitrocellulose using a semi-dry apparatus (E&K, Saratoga, CA).
The filters were then blocked in PBS containing 0.1% Tween-20 (TBS)
and 5% nonfat dry milk, incubated in TBS with 1% nonfat dry milk and
primary antibody at dilutions from 1:1,000 to 1:10,000 for 60 min at room
temperature, washed three times in TBS, and incubated in appropriate
secondary antibody conjugated to peroxidase for an additional 60 min be-
fore washing in TBS and visualization by enhanced chemiluminescence
(Amersham Intl., Arlington Heights, IL).
 
Organelle Immunoisolation
 
Dynal beads (M-450) conjugated to secondary anti–mouse antibody were
coated with monoclonal antibodies to either synaptophysin (Sigma Chem-
ical Co.) or transferrin receptor (H68.4, a generous gift of I. Trowbridge,
Scripps Research Institute, La Jolla, CA) by incubation overnight in
Ca
 
11
 
- and Mg
 
11
 
-free PBS containing 2% FCS (immunoisolation buffer)
followed by four washes in the same buffer. For each reaction, 20 
 
m
 
l of
beads was mixed with 160 
 
m
 
l immunoisolation buffer and either 30 
 
m
 
l
postnuclear supernatant or 60 
 
m
 
l from a density gradient fraction. The re-
action mixture was incubated for 1 h at 4
 
8
 
C and washed four times with the
same buffer. The immunoisolated vesicles were then extracted in sample
buffer and subjected to Western analysis.
 
Acetylcholine Transport Assay
 
A postnuclear supernatant (S1) was prepared from either PC12 cells or
CHO cells as described above but in 80 mM potassium tartrate, 20 mM
Hepes, pH 6.8, 0.5 mM EGTA, 1 mM ascorbic acid, 2 
 
m
 
g/ml leupeptin,
0.2 mM DFP, and 50 
 
m
 
M echothiophate (Wyeth-Ayerst, Philadelphia, PA;
58; homogenization buffer). The P2 fraction was collected by sedimentation
at 27,000 
 
g
 
 for 35 min at 4
 
8
 
C. Sedimentation of the S2 at 200,000 
 
g
 
 for 60
min yielded the P3 fraction, and both P2 and P3 were resuspended in ho-
mogenization buffer before assay as previously described (34, 58). Briefly,
100–200 
 
m
 
g protein in 50 
 
m
 
l was added to an equal volume of 100 mM po-
tassium tartrate, 20 mM Hepes, pH 7.4, 1 mM ascorbic acid, and 50 
 
m
 
M
echothiophate (transport buffer) with or without 50 
 
m
 
M vesamicol (RBI)
and 5 
 
m
 
M carbonylcyanide-
 
m
 
-chlorophenylhydrazone (CCCP; Sigma
Chemical Co.). Uptake was initiated by adding 100 
 
m
 
l transport buffer
containing 0.8 mM 
 
3
 
H-ACh (Dupont NEN), 10 mM ATP, and 10 mM
MgSO
 
4
 
. After incubation at 29
 
8
 
C for varying intervals, the reaction was
terminated by rapid filtration through 0.2 
 
m
 
m Supor 200 filters (Gelman
Sciences, Ann Arbor, MI), followed by three washes with cold transport
buffer. The radioactivity bound to the filters was then measured by scintil-
lation counting in 2.5 ml Cytoscint (ICN Biomedicals, Costa Mesa, CA).
Uptake for 0 min at 29
 
8
 
C was subtracted as background.
 
Results
 
Antibody Production and Expression of VAChT in 
CHO and PC12 Cells
 
To localize VAChT in vivo as well as in cultured cells, we
raised rabbit polyclonal antibodies to a peptide derived
from the COOH terminus of the protein predicted by the
rat cDNA. Coupling of the peptide to KLH through an NH
 
2
 
-
terminal cysteine using MBS has enabled production of
antibodies to both VMATs (36, 46), and we have used a
similar approach for VAChT. Like a bacterial fusion pro-
tein derived from the same region of VAChT (21), a COOH-
terminal peptide generated antibodies of high titer that rec-
ognize several immunoreactive species in COS cells trans-
fected with the VAChT cDNA but not in cells transfected
with the vector alone or with the VMATs (data not shown).
We used the anti-peptide VAChT antibody to isolate
stably transfected CHO and PC12 cells that express VAChT.
After transfection and selection in the neomycin analog
G418, we screened stable transformants by immunocy-
tochemistry, using cell clones with mild to moderate VAChT
expression for further study. Fig. 1 shows that untrans-
fected CHO cells express no rat VAChT (rVAChT), as
anticipated for a fibroblast cell line. A stable CHO trans-
formant, however, expresses high levels of several immu-
noreactive species by Western analysis. These include an
 
z
 
30-kD form that is reduced in the presence of protease
inhibitors (data not shown) and thus appears to derive
from the 
 
z
 
70-kD form by proteolysis in vitro. Wild-type
PC12 cells express very low levels of endogenous rVAChT
(Fig. 1 
 
A
 
). Since these levels limit the analysis, we have
also isolated stable PC12 transformants overexpressing
VAChT. The PC12 cell clone described here has higher,
more easily detectable levels of rVAChT expression, with
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an 
 
z
 
30-kD species similar to that observed in CHO cells
but with a higher molecular species of 
 
z
 
80 kD as well that
corresponds to the major form observed in vivo using brain
extracts (21). Although the large difference in expression
makes it difficult to compare the immunoreactive species
in transfected and untransfected PC12 cells, they appear to
differ primarily in intensity rather than size. To character-
ize the differences in size between transfected PC12 and
CHO cells, we used N-glycanase (Fig. 1 
 
B
 
). Digestion by this
enzyme reduces the immunoreactive proteins to the same
size in both cell types, indicating that they differ only in
the amount of N-linked carbohydrate. Indeed, we have
previously observed that the glycosylation of VMATs shows
similar differences between PC12 and CHO cells (36). Thus,
expression of the VAChT cDNA in these two cell lines
produces similar immunoreactive proteins. In addition,
the anti-peptide antibody recognizes VAChT with high af-
finity and specificity, and the serum was used directly for
subsequent studies without further purification.
 
Localization of VAChT in SLMVs of PC12 Cells
 
Previous studies have shown that SVs store ACh and ex-
hibit ACh transport activity (45). More recently, VAChT
has been localized to SVs in vivo (21, 61). However, the
extent to which VAChT differs from the closely related
VMATs in terms of sorting remains unclear. To compare
directly the localization of VAChT and VMATs, we used
PC12 cells, which store ACh and monoamines in appar-
ently distinct vesicular compartments (3). Indeed, we have
previously localized endogenous VMAT1 to LDCVs in PC12
cells (36), and VMAT2 appears to sort even more strin-
gently to this regulated secretory pathway (Liu, Y., and
R.H. Edwards, unpublished observations).
Using the anti-peptide antibodies, we first localized en-
dogenous VAChT in untransfected PC12 cells by immuno-
fluorescence. Fig. 2 shows that VAChT immunoreactivity
appears in both the cell bodies and processes of NGF-
treated cells. This coincides with the pattern observed by
double immunofluorescence of the same cells for synapto-
physin, a marker of SLMVs that also occurs in endosomes
(8, 27), suggesting that VAChT localizes preferentially to
SLMVs and endosomes. In contrast, immunofluorescence
for chromogranin B, a marker of LDCVs, occurs princi-
pally at the tips of processes with only low levels of expres-
sion in cell bodies. This different pattern of expression
suggests that VAChT does not localize significantly to
LDCVs in PC12 cells. However, the low levels of endoge-
nous VAChT expression preclude further analysis of its
localization by biochemical methods.
To determine the localization of VAChT by quantita-
tive methods such as density gradient fractionation, we
have increased VAChT expression in PC12 cells using a
variety of methods. We present the results obtained with a
stable PC12 transformant, but a viral expression system
has yielded similar findings (data not shown). To exclude
the possibilities that overexpression of VAChT or that
Figure 1. Western analysis of membranes from transfected CHO
and PC12 cells. (A) An anti-peptide antibody recognizes VAChT
in transfected CHO and PC12 cells. Western analysis of mem-
branes prepared by differential centrifugation from CHO (left)
and PC12 cells (right) shows that wild-type (wt) CHO cells ex-
press no immunoreactive VAChT, whereas a stable CHO trans-
formant (VAChT) contains multiple immunoreactive forms. The
two major species of z70 and z30 kD are indicated by the lower
two arrows. Wild-type (wt) PC12 cells show several immunoreac-
tive forms, most of which appear at higher levels in the stable
transformant overexpressing rat VAChT. In PC12 cells, the two
major species of z80 and z30 kD are indicated by the upper and
lower arrows. Molecular masses in kD are shown to the left. (B)
VAChT undergoes N-linked glycosylation in PC12 and CHO
transformants. A postnuclear supernatant prepared from either
PC12 cells (left) or CHO cells (right) was incubated overnight at
378C in the presence (1) and absence (2) of N-glycanase. The ar-
rows on the right indicate the undigested forms and the arrow-
head the digested form of VAChT. VAChT thus undergoes
N-linked glycosylation in both PC12 and CHO cells, and the extent
of glycosylation differs in the two cell lines. Molecular masses (in kD)
are indicated to the left.
Figure 2. VAChT colocalizes with synaptophysin in wild-type PC12
cells by immunofluorescence. Wild-type PC12 cells were stained
with antibodies to VAChT (a and c), synaptophysin (b), and
chromogranin B (d). For double immunofluorescence of the two
sets of cells (a and b and c and d), the rabbit polyclonal antibody
to VAChT was detected with a secondary antibody conjugated to
fluorescein and the mouse monoclonal antibodies to synapto-
physin and chromogranin B were detected with a secondary anti-
body conjugated to rhodamine. VAChT immunoreactivity occurs
at both the tips of processes and in the cell body (a and c) and
colocalizes with synaptophysin at these sites (b). In contrast,
chromogranin B occurs predominantly at the tips of processes
with very little at the cell body (d), a pattern clearly distinct from
that of VAChT (c). Bars, 10 mm.
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variation in the PC12 cell clone might produce anomalous
mislocalization of the introduced protein, however, we
first repeated the immunofluorescence study using the sta-
ble transformant and confocal laser microscopy. Fig. 3, 
 
a
 
and 
 
d
 
, shows that VAChT immunoreactivity in the PC12
clone also occurs in the cell body as well as the processes.
Double staining with the SLMV marker synaptophysin
(Fig. 3, 
 
b
 
 and 
 
c
 
) shows colocalization with VAChT at a
juxta-nuclear  site in the cell body and partial colocalization
in the processes. In contrast, the LDCV marker chromo-
granin B (Fig. 3, e and f) shows a complementary localiza-
tion in processes rather than the cell body. Thus, heterolo-
gous expression of VAChT in this PC12 transformant does
not appear to have significantly altered its localization
from that of the endogenous protein, at least by immuno-
fluorescence. Further, immunoisolation of a postnuclear
supernatant with the synaptophysin antibody quantita-
tively precipitates all the VAChT in the starting material
(Fig. 4 B), supporting the colocalization of VAChT and
synaptophysin in this cell clone.
Using the stable PC12 transformant, we have deter-
mined the localization of VAChT by velocity gradient
fractionation (Fig. 4 A). Velocity sedimentation through
glycerol separates SLMVs from endosomes, LDCVs, and
other membrane compartments. By Western analysis, syn-
aptophysin appears both in a peak in the middle of the
gradient (Fig. 4 A, fractions 5–8) that represents SLMVs
and at the bottom where it presumably occurs in endo-
somes (Fig. 4 A). Both high and low molecular weight
forms of VAChT show a peak of similar shape in the mid-
dle of the gradient at the same position as synaptophysin,
suggesting localization of VAChT in SLMVs. In addition,
VAChT appears at the bottom of the gradient where, like
synaptophysin, it presumably occurs in other membranes
such as endosomes. To determine whether VAChT actu-
ally occurs on SLMVs, we immunoisolated vesicles from
the middle of the gradient with a monoclonal antibody to
synaptophysin (Fig. 4 C). The synaptophysin antibody pre-
cipitates essentially all of the VAChT from these fractions,
whereas a control with no antibody precipitates none of
the protein. Thus, VAChT occurs on the same population
of SLMVs as synaptophysin.
To determine whether VAChT occurs on other mem-
brane compartments in addition to SLMVs, we used equi-
librium sedimentation through sucrose (Fig. 5). SLMVs and
endosomes migrate near the top of this gradient, as shown
by immunostaining for synaptophysin and TfR, respec-
tively. In contrast, very little synaptophysin occurs toward
the bottom of the gradient where LDCVs migrate, as indi-
cated by the immunoreactivity for secretogranin II (Fig. 5,
fractions  10–14). Like synaptophysin, VAChT also ap-
pears relatively restricted to the top of the gradient. How-
ever, the peak of VAChT immunoreactivity is broad and
does not coincide precisely with that for synaptophysin,
suggesting expression in additional vesicular compartments.
Indeed, VAChT immunoreactivity also cofractionates with
Figure 3. Colocalization of VAChT with synaptophysin in a sta-
ble PC12 cell transformant. A stable PC12 cell transformant
overexpressing VAChT was immunostained for VAChT (a and
d), synaptophysin (b), and chromogranin B (e). Using two sets of
cells (a–c and d–f) for confocal laser microscopy, the rabbit poly-
clonal antibody to VAChT was detected with a secondary anti–
rabbit antibody conjugated to Cy3 (a and d, green), and the
mouse monoclonal antibody to synaptophysin was detected with
a secondary anti–mouse antibody conjugated to Cy5 (b and e,
red). The superimposed staining is shown in c and f. Similar to
wild-type PC12 cells, VAChT (a) colocalizes with synaptophysin
(b) at both the tips of processes and at a juxtanuclear region in
the cell body (c, yellow). Despite the overexpression of VAChT
in this cell line, VAChT immunoreactivity (d) appears quite dis-
tinct from chromogranin B (e), which occurs predominantly at
the tips of processes and only at lower levels in the cell body (f,
yellow). Bars, 10 mm.
Figure 4. VAChT localizes to SLMVs by velocity sedimentation
through glycerol and immunoisolation. (A) A stable PC12 trans-
formant overexpressing VAChT was disrupted by homogeniza-
tion and the postnuclear supernatant subjected to velocity sedi-
mentation through a gradient of 5 to 25% glycerol. Western
analysis of the fractions shows that both high and low molecular
weight forms of VAChT (arrows) appear at a position in the mid-
dle of the gradient that coincides with synaptophysin and corre-
sponds to SLMVs. Larger amounts of both VAChT and synapto-
physin also occur at the bottom of the gradient in fractions that
include endosomes. Molecular mass markers (in kD) are indi-
cated at the left. Fractions are numbered from the top of the gra-
dient on the left to the bottom on the right. (B) A postnuclear su-
pernatant was subjected to immunoisolation using Dynal beads
coated with a monoclonal antibody to synaptophysin. Western
analysis using the antibody to VAChT shows substantial immu-
noreactivity in the starting material (lane 1) and almost full re-
covery in the immunoisolated vesicles (lane 2). Immunoisolation
with uncoated Dynal beads yields minimal VAChT immunoreac-
tivity (lane 3). Immunostaining for synaptophysin (Syp) shows an
identical pattern, confirming the colocalization of VAChT and
synaptophysin. (C) Fraction 6 from the glycerol gradient was sub-
jected to immunoisolation as described in B. Western analysis using
the antibody to VAChT shows immunoreactivity in the starting
material (lane 1) and essentially full recovery in the immunoiso-
lated vesicles (lane 2). Control immunoisolation with uncoated
Dynal beads yields no VAChT immunoreactivity (lane 3). Immu-
nostaining for synaptophysin shows an identical pattern, confirm-
ing the colocalization of VAChT and synaptophysin on the same
population of SLMVs.
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endosomal membranes expressing TfR. Nonetheless, the
peak of VAChT immunoreactivity is clearly distinct from
that for secretogranin II, indicating considerably lower
levels of VAChT on LDCVs than on lighter vesicles such
as SLMVs.
VAChT Occurs on LDCVs
Although the results indicate preferential localization of
VAChT to light membranes in PC12 cells including SLMVs
and endosomes, the immunofluorescence studies and den-
sity gradient fractionation cannot exclude VAChT expres-
sion on LDCVs. Localization by immunofluorescence at
the tips of processes coincides with the localization of LD-
CVs as well as SLMVs, and the peak of VAChT expression
by equilibrium sedimentation through sucrose partially over-
laps with that for secretogranin II, raising the possibility
that low levels of VAChT occur in LDCVs. Indeed, synap-
tophysin occurs at low levels on LDCVs (13, 28), suggest-
ing that VAChT may as well. To determine whether VAChT
occurs on LDCVs, we have purified LDCVs using a two-
step procedure (52). After loading PC12 cells overnight
with [3H]norepinephrine to label the LDCVs, a postnu-
clear supernatant was subjected to velocity sedimentation
through sucrose. This gradient separates LDCVs from a
variety of membranes including endoplasmic reticulum,
synaptic vesicles, and endosomes. Fractions containing
LDCVs were then identified by scintillation counting and
subjected to equilibrium sedimentation through sucrose.
As a result of the first gradient, the second provides better
separation of LDCVs from other membrane fractions, en-
abling detection of small amounts of proteins in LDCVs
that occur at larger amounts in other compartments. In-
deed, Fig. 6 shows a single peak of both synaptophysin and
VAChT on this gradient, and in contrast to Fig. 5, which
shows most of these proteins in lighter fractions, this single
peak coincides with the peak of secretogranin II. Impor-
tantly, the profile of VAChT on this gradient clearly differs
from that of ribophorin II, a marker for the endoplasmic
reticulum. Thus, low levels of both VAChT and synap-
tophysin do occur specifically on LDCVs. Nonetheless,
VAChT clearly differs in localization from the closely re-
lated VMATs, which occur predominantly on LDCVs.
VAChT Activity in PC12 Cells
In addition to the difference in localization of VAChT and
VMATs in PC12 cells, the proteins have also appeared to
differ in transport activity when expressed in a variety of
cell lines. The VMATs show robust transport activity in a
number of cells, but it has been more difficult to demon-
strate VAChT activity. An initial report suggested uptake
of ACh into intact CV-1 fibroblast cells expressing VAChT
(19), but the apparent inability to demonstrate transport
using either semipermeabilized cells or a membrane prep-
aration precluded further characterization of the activity.
More recently, a stable PC12 transformant expressing
VAChT has been demonstrated to transport ACh with the
expected functional characteristics (58). Indeed, we have
identified ACh transport activity in a preparation of light
membrane vesicles from transfected PC12 cells (Fig. 7 A).
As anticipated, vesamicol inhibits this activity, and un-
transfected cells exhibit considerably less ACh transport.
The apparent discrepancy in function between expres-
sion of VAChT in fibroblast and neural cells raises the
possibility that the localization in PC12 cells may be cru-
cial for function. To address this possibility, we first mea-
sured [3H]ACh transport in different membrane fractions
from the transfected PC12 cells. Fig. 7 B shows little vesa-
micol-sensitive transport above background in a heavy
Figure 5. VAChT predominates in light membrane fractions by
equilibrium sedimentation through sucrose. A postnuclear super-
natant from PC12 cells overexpressing VAChT was subjected to
equilibrium sedimentation through a gradient of 0.6 to 1.6 M su-
crose. Western analysis shows that VAChT occurs in light mem-
brane fractions as a very broad peak that coincides with the peak
for synaptophysin, a marker of SLMVs and transferrin receptor
(TfR), a marker of endosomes. Secretogranin II indicates frac-
tions containing LDCVs, which migrate as a peak distinct from
VAChT and synaptophysin. However, the peak of VAChT im-
munoreactivity overlaps with that of secretogranin II. Molecular
mass markers (in kD) are indicated on the left and high and low
molecular weight forms of VAChT are indicated by arrows on
the right. Fractions were collected from the top of the gradient
(left) to the bottom (right).
Figure 6. VAChT occurs on
LDCVs by two-step density
gradient fractionation. PC12
cells stably overexpressing
VAChT were incubated over-
night in medium containing
0.25 mCi/ml [3H]norepineph-
rine, disrupted by homogeni-
zation, and a postnuclear su-
pernatant subjected to two
steps of density gradient frac-
tionation. In the first step,
the membranes were separated by velocity sedimentation
through a gradient of 0.3 to 1.2 M sucrose. Radioactive fractions
containing LDCVs in the middle of the gradient were then
pooled and subjected to equilibrium sedimentation through a
gradient of 0.6 to 1.6 M sucrose. Fractions from the second gradi-
ent show VAChT immunoreactivity that coincides with the
LDCV marker secretogranin II as well as synaptophysin. How-
ever, some of the synaptophysin also occurs on slightly less dense
vesicles that coincide with the endoplasmic reticulum marker ri-
bophorin II. Molecular mass standards (in kD) are shown to the
left and arrows indicating the two species of VAChT to the right.
Fractions from the second gradient were collected from the top
(left) to the bottom (right).
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membrane fraction (Fig. 7 B, P2) prepared from the stable
PC12 transformant. However, a light membrane fraction
(Fig. 7 B, P3) exhibits robust transport activity that is in-
hibited by both vesamicol and, as expected from a known
proton exchanger such as VAChT, the proton ionophore
carbonyl cyanide m-chlorophenylhydrazone (CCCP). West-
ern analysis demonstrates equivalent levels of VAChT
protein and substantial amounts of the endosomal TfR in
both fractions, but P2 clearly contains more LDCVs, as
demonstrated by immunostaining for secretogranin, and
P3 contains more SLMVs as shown by staining for synap-
tophysin (Fig. 7 C). Thus, VAChT activity correlates more
with expression in SLMVs rather than simply the amount
of the protein or its presence in endosomes, supporting the
possibility that localization of VAChT to SLMVs may be
crucial for function and may account for the apparent ab-
sence of detectable activity in non-neural cells. However,
we also reexamined the expression of VAChT in CHO fi-
broblasts.
VAChT Activity in CHO Cells
To assess the localization of VAChT in non-neural cells,
we have used a stable CHO transformant that also ex-
presses VMAT1. Immunofluorescence shows particulate
cytoplasmic staining for VAChT (Fig. 8). Strong immu-
noreactivity also occurs next to the nucleus, a pattern ob-
served for VMAT1 as well and apparently representing the
microtubule organizing center (36). To determine whether
these intracellular vesicles were endosomes, we loaded the
same cells with a fluorescent form of transferrin. After in-
ternalization, the fluorescence of preloaded transferrin en-
tirely coincides with the pattern of VAChT, indicating ex-
pression of the transporter in endosomes. VMAT1 shows
a similar pattern of expression in CHO cells (36), further
suggesting that VAChT colocalizes with VMATs in this
cell line.
We have also examined the localization of VAChT in
CHO cells by sucrose density gradient fractionation. Equi-
librium sedimentation of extracts from cells expressing
VAChT shows a broad peak in the middle of the gradient
(Fig. 9 A). The peak of VAChT immunoreactivity coin-
cides with the peak of TfR as a marker for endocytic vesi-
cles, further supporting the localization of VAChT to en-
dosomes. Importantly, VMAT1 also expressed by these
same stable transformants shows an identical pattern of lo-
calization. To confirm the localization in endosomes, we
also isolated membrane vesicles from the pooled light frac-
tions using an antibody to the TfR. The immunoisolated
membranes contain a substantial proportion of total cellu-
lar VAChT, whereas control membranes isolated without
antibody show little VAChT (Fig. 9 B). Thus, the results
indicate that, in contrast to PC12 cells, VAChT colocalizes
with VMATs in the endosomes of CHO fibroblasts.
Since the VMATs function in CHO cells and VAChT
colocalizes with VMATs in this cell line, we assessed ACh
transport activity in a postnuclear supernatant prepared
from a CHO cell clone stably expressing VAChT. In con-
trast to membranes from untransfected cells (data not
shown), vesicles from the transfected CHO cells accumu-
late [3H]ACh in a vesamicol-sensitive manner (Fig. 10).
This result indicates that VAChT does not require expres-
sion in a neural cell or in SLMVs to function.
Figure 7. VAChT overex-
pression in PC12 cells con-
fers vesicular ACh transport
activity. (A) A population of
light membrane vesicles (P3)
from transfected PC12 cells
(PC12[VAChT];  filled squares)
demonstrates ACh transport
activity substantially higher
than in the same vesicles from
untransfected cells (wt PC12;
filled triangles). In addition, vesamicol inhibits the uptake by transfected cells (open squares) to a level lower than in untransfected cells,
suggesting that endogenous PC12 cell VAChT has some transport activity. (B) Comparison of ACh uptake by different fractions from
transfected PC12 cells. Membranes from a postnuclear supernatant collected by centrifugation at 27,000 g for 35 min (P2) show less ve-
samicol- and CCCP-sensitive ACh transport activity than membranes collected by centrifugation of the S2 at 200,000 g for 40 min (P3).
ACh uptake is normalized to background accumulation in the presence of vesamicol for each of the membrane preparations. (C) West-
ern analysis of equal amounts of protein from P2 and P3 fractions shows approximately equal amounts of VAChT and substantial
amounts of transferrin receptor (TfR) in both fractions but considerably more of the LDCV marker secretogranin II (SgII) in P2 and
more of the SLMV marker synaptophysin (Syp) in P3.
Figure 8. VAChT immuno-
fluorescence colocalizes with
transferrin receptors in trans-
fected CHO cells. CHO cells
expressing VAChT were pre-
loaded with transferrin conju-
gated to Texas red. Double
immunofluorescence of the
same cells shows that the
particulate cytoplasmic local-
ization of internalized trans-
ferrin (a) coincides with the
distribution of VAChT im-
munoreactivity (b). Thus,
VAChT colocalizes with
transferrin receptor in an en-
docytic compartment. Both
VAChT and transferrin re-
ceptor also appear in a peri-
nuclear compartment that
occurs at the microtubule
organizing center (36). Bar,
10  mm.
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Discussion
We have characterized the localization of VAChT in PC12
cells. Immunofluorescence shows a pattern of staining sim-
ilar to the SLMV marker synaptophysin and distinct from
the LDCV marker secretogranin. Sucrose density gradient
fractionation also indicates high levels of VAChT on light
membrane vesicles consistent with location on SLMVs and
endosomes. Further, velocity sedimentation through glyc-
erol and immunoisolation of a light fraction from this gra-
dient with an antibody to synaptophysin confirms VAChT
localization to SLMVs. This distribution presumably ac-
counts for the storage of ACh in SVs, consistent with clas-
sical observations of quantal ACh release from SVs at the
neuromuscular junction, with previous studies of ACh
storage and release from PC12 cells (3, 5, 23, 40, 49) and
with more recent observations of VAChT localization to SVs
in brain by immunoelectron microscopy (21, 61). However,
the velocity gradient also demonstrates considerable amounts
of VAChT in larger membranes, presumably endosomes.
Synaptophysin also occurs at high levels in these endosomal
fractions, apparently reflecting the inefficient biogenesis
of SLMVs in PC12 cells. In addition, VAChT resides at low
levels on LDCVs purified by sequential density gradient
fractionation. Thus, VAChT localizes preferentially but not
exclusively to SLMVs and endosomes in PC12 cells. 
Although closely related in sequence, VAChT and the
VMATs differ in steady-state localization in PC12 cells. In
contrast to VAChT, VMAT1 localizes predominantly to
LDCVs (36). Small amounts of VMAT1 occur on SLMVs
in PC12 cells but at a much lower level than on heavy
membrane fractions. In the brain, VMAT2 localizes to
synaptic vesicles and other membranous structures (41,
42). However, VMAT2 expressed in PC12 cells occurs al-
most exclusively on LDCVs, with essentially none detect-
able on lighter membrane fractions (Liu, Y., and R.H. Ed-
wards, unpublished observations). Thus, the predominant
localization of VAChT to SLMVs and endosomes in PC12
cells differs markedly from the preferential localization of
VMATs to LDCVs. The differences in steady-state local-
ization of these closely related proteins presumably reflect
differences in their membrane trafficking.
Dense core vesicles differ from synaptic vesicles in terms
of biogenesis as well as in content and mode of release.
LDCVs form at the TGN, where their contents appear to
sort away from the constitutive secretory pathway (20, 56).
In contrast, SVs form at the nerve terminal (8, 11, 47). Pro-
teins destined for SVs enter the constitutive secretory
pathway at the TGN, arrive at the cell surface, and then
undergo endocytosis to form SVs (54). Thus, membrane
proteins destined for SVs sort away from the regulated
secretory pathway (LDCVs) at the TGN. Since VAChT
occurs predominantly on SLMVs and endosomes in PC12
cells, whereas VMATs localize preferentially to LDCVs in
the regulated pathway (36, 61), the TGN appears to sort
these proteins to distinct secretory pathways.
The mechanisms involved in sorting to the regulated
and constitutive secretory pathways remain unclear. Solu-
ble proteins destined for the regulated pathway appear to
aggregate under the appropriate conditions, indicating
that they sort as a result of their general biophysical prop-
erties rather than through a specific signal (57). On the
other hand, membrane proteins may sort to LDCVs
through a direct interaction of their cytoplasmic domains
with cytosolic proteins, a process that occurs in the reten-
tion of resident endoplasmic reticulum proteins (12), sort-
ing to lysosomes (25), and in endocytosis (10, 43). How-
ever, very few integral membrane proteins have been
identified that clearly sort to the regulated secretory path-
way (14, 31). VMATs are such integral membrane pro-
teins, and the close relationship to VAChT further sug-
gests that a domain present in VMATs but absent from
VAChT may mediate the interaction with cytosolic ma-
chinery involved in the formation of LDCVs. In this
Figure 9. VAChT localizes
to endosomes in CHO cells
by density gradient fraction-
ation and immunoisolation.
(A) CHO cells expressing
both VAChT and VMAT1
were homogenized and a
postnuclear supernatant sep-
arated by equilibrium sedi-
mentation through 0.6 to 1.6
M sucrose. Western analysis
of the fractions shows comi-
gration of VAChT with
transferrin receptor (TfR),
supporting the localization to
endosomes indicated by
immunofluorescence. Fur-
ther, the peak of VAChT im-
munoreactivity coincides with that for VMAT1, suggesting that
in contrast to PC12 cells, where they do not localize to the same
membranes, VAChT and VMAT1 may colocalize in CHO cells.
Molecular mass standards (in kD) are shown to the left and the
two forms of VAChT indicated with arrows to the right. Frac-
tions were collected from the top (left) to the bottom (right). (B)
Fraction 7 from the sucrose gradient was subjected to immu-
noisolation using Dynal beads coated with a monoclonal anti-
body to the cytoplasmic domain of the transferrin receptor
(H68.4). Western analysis using the antibody to VAChT shows
immunoreactivity in the starting material (lane 1) and substantial
but not complete recovery in the immunoisolated vesicles (lane
2). Immunoisolation with uncoated Dynal beads yields trace lev-
els of VAChT immunoreactivity (lane 3), supporting the speci-
ficity of the immunoisolation. Immunostaining for transferrin re-
ceptor (TfR) shows a similar pattern of incomplete recovery.
Densitometry indicates that at least 20% of the total VAChT in
this light membrane fraction coexists with the transferrin recep-
tor, presumably on endosomal vesicles.
Figure 10. VAChT expres-
sion in CHO cells confers
ACh transport activity. A
postnuclear supernatant pre-
pared from CHO cells stably
expressing VAChT demon-
strates uptake of [3H]ACh
(filled squares), which is sen-
sitive to vesamicol (open
squares). Membranes from
untransfected cells do not
exhibit vesamicol-dependent
ACh transport (data not
shown).
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model, trafficking to the regulated secretory pathway de-
pends on a specific sorting event, whereas constitutive se-
cretion occurs by default. However, it is also possible that
the VAChT found in LDCVs may be removed from these
vesicles as they mature.
During the process of LDCV maturation after budding
from the TGN, proteins destined for lysosomes or consti-
tutive secretion are removed from LDCVs (32, 33). Indeed,
clathrin and its associated proteins associate in patches with
the surface of immature secretory granules, suggesting that
they may participate in selective budding and the removal
of constitutively secreted proteins (15, 44, 56). VAChT
may therefore undergo specific exclusion or removal from
LDCVs. In this model, sorting of the VMATs to LDCVs
could occur by default.
The mechanisms involved in sorting to the regulated
and constitutive secretory pathways and hence the differ-
ences in trafficking between VMATs and VAChT remain
poorly understood. However, the availability of two closely
related integral membrane proteins that sort divergently
into the two secretory pathways provides a way to address
basic questions about the biogenesis of secretory vesicles.
Interestingly, immunoelectron microscopy has localized
VMAT2 to vesicles budding off the TGN that contain a
dense core (41), whereas VAChT has a more diffuse local-
ization in the Golgi complex (21), supporting the first model
of specific sorting to the regulated secretory pathway.
Differential localization of VAChT and the VMATs in
PC12 cells raises the possibility that the two types of trans-
porter also sort differently in fibroblasts. Indeed, a recent
report suggests that although fibroblasts release most se-
creted proteins constitutively, they retain a fraction and
secrete these upon stimulation, suggesting the presence of
a regulated secretory pathway (9). Since the VMATs sort
to LDCVs in PC12 cells, they may also sort to this regu-
lated pathway in fibroblasts and so acquire the capacity to
function. The location of VAChT, which sorts to the con-
stitutive pathway in PC12 cells, may thus differ from the
VMATs in CHO cells as well, possibly accounting for the
absence of detectable VAChT function in previous studies
using non-neural cells (19, 48, 58). One report has also de-
scribed uptake into whole cells (19), suggesting the pres-
ence of VAChT at the cell surface. Thus, we have also de-
termined the localization of VAChT in CHO fibroblasts.
The results show substantial steady-state expression of
VAChT in an endocytic compartment in CHO cells. Im-
munofluorescence, density gradient fractionation, and im-
munoisolation indicate extensive colocalization of VAChT
with internalized TfR. Previous studies have demonstrated
that other synaptic vesicle proteins localize to endosomes
when expressed in fibroblast cell lines (8, 27). Presumably,
the acidic nature of this compartment provides the driving
force for active transport by the VMATs, and VMAT1
does localize to endosomes in CHO cells (36). In addition,
we now show that VAChT colocalizes with VMAT1 ex-
pressed in the same cells. These observations in CHO cells
support the impression that VAChT, like synaptophysin
and other SV proteins, contains signals for endocytosis
that function in fibroblasts as well as in neuroendocrine
cells. The results also suggest that differences in localiza-
tion cannot account for the inability to detect ACh trans-
port, at least in CHO cells. Rather, the lack of transport
may derive from the absence of a required cofactor in non-
neural cells.
PC12 cells stably expressing VAChT have previously
been shown to exhibit vesicular ACh transport (58). To as-
sess the role of localization in this activity, we prepared a
fraction of light membrane vesicles (P3) from PC12 cells
overexpressing VAChT. These membranes exhibit accu-
mulation of [3H]ACh sensitive to the inhibitor vesamicol.
Interestingly, a heavier membrane fraction (P2) shows lit-
tle if any specific ACh transport activity but contains al-
most equivalent amounts of VAChT to P3. Western analy-
sis further demonstrates that the P3 fraction contains much
more synaptophysin but considerably less secretogranin II
than the P2 fraction, suggesting that expression in SLMVs
or endosomes rather than in LDCVs may be required for
transport activity. 
To determine whether localization to SLMVs is required
for ACh transport activity, we used the stable CHO trans-
formant expressing VAChT. A postnuclear supernatant
prepared from these cells shows substantial vesamicol-sen-
sitive accumulation of [3H]ACh. Thus, VAChT can func-
tion in the endosomes of non-neural cells and does not ap-
pear to require specific synaptic vesicle proteins or other
cofactors.
In summary, we demonstrate the differential localization
in PC12 cells of the closely related vesicular transporters
for ACh and monoamines. VAChT localizes preferentially
to SLMVs and endosomes, whereas the VMATs localize
predominantly to LDCVs. Since SV proteins use the con-
stitutive, secretory pathway to reach the cell surface be-
fore recycling to SVs, the results suggest that VAChT and
the VMATs sort divergently in the TGN, VAChT to the
constitutive, and VMATs to the regulated secretory path-
way. As integral membrane proteins, the restricted se-
quence differences between VAChT and the VMATs may
thus provide a tool to dissect the mechanism of differential
sorting in the TGN. In addition, we find that VAChT func-
tions in non-neural as well as neural cells and so does not
require expression with other SV proteins for activity.
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